Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

References

• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med200535298799615758009
   PubMed Web of Science ®Google Scholar
• MischelPSCloughesyTFTargeted molecular therapy of GBMBrain Pathol200313526112580545
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature20084551061106818772890
   PubMed Web of Science ®Google Scholar
• EkstrandAJSugawaNJamesCDCollinsVPAmplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tailsProc Natl Acad Sci U S A199289430943131584765
   PubMed Web of Science ®Google Scholar
• FrederickLWangXYEleyGJamesCDDiversity and frequency of epidermal growth factor receptor mutations in human glioblastomasCancer Res2000601383138710728703
   PubMed Web of Science ®Google Scholar
• HayashiYUekiKWahaAWiestlerODLouisDNvon DeimlingAAssociation of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiformeBrain Pathol199778718759217972
   PubMed Web of Science ®Google Scholar
• KleihuesPOhgakiHPrimary and secondary glioblastomas: from concept to clinical diagnosisNeuro Oncol19991445111550301
   PubMedGoogle Scholar
• KuanCTWikstrandCJBignerDDEGF mutant receptor vIII as a molecular target in cancer therapyEndocr Relat Cancer20018839611397666
   PubMed Web of Science ®Google Scholar
• NaganeMLinHCaveneeWKHuangHJAberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implicationsCancer Lett.2001162SupplS17S2111164186
   PubMedGoogle Scholar
• NishikawaRJiXDHarmonRCA mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicityProc Natl Acad Sci U S A199491772777318052651
   PubMed Web of Science ®Google Scholar
• SmithJSTachibanaIPasseSMPTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiformeJ Natl Cancer Inst2001931246125611504770
   PubMed Web of Science ®Google Scholar
• WatanabeKTachibanaOSataKYonekawaYKleihuesPOhgakiHOverexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomasBrain Pathol19966217223 discussion 23–248864278
   PubMed Web of Science ®Google Scholar
• WikstrandCJReistCJArcherGEZalutskyMRBignerDDThe class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic targetJ Neurovirol199841481589584952
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-Kinase AKT pathway in human cancerNat Rev Cancer2002248950112094235
   PubMed Web of Science ®Google Scholar
• LiuWJamesCDFrederickLAldereteBEJenkinsRBPTEN/MMAC1 mutations and EGFR amplification in glioblastomasCancer Res199757525452579393744
   PubMed Web of Science ®Google Scholar
• SchmidtEEIchimuraKGoikeHMMoshrefALiuLCollinsVPMutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenograftsJ Neuropathol Exp Neurol1999581170118310560660
   PubMed Web of Science ®Google Scholar
• AdjeiAADavisJNBruzekLMErlichmanCKaufmannSHSynergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell linesClin Cancer Res200171438144511350915
   PubMed Web of Science ®Google Scholar
• FeldkampMMLalaPLauNRoncariLGuhaAExpression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimensNeurosurgery1999451442145310598712
   PubMed Web of Science ®Google Scholar
• BoglerOHuangHJKleihuesPCaveneeWKThe p53 gene and its role in human brain tumorsGlia1995153083278586466
   PubMed Web of Science ®Google Scholar
• MomandJZambettiGPOlsonDCGeorgeDLevineAJThe mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell199269123712451535557
   PubMed Web of Science ®Google Scholar
• KamijoTWeberJDZambettiGZindyFRousselMFSherrCJFunctional and physical interactions of the ARF tumor suppressor with p53 and Mdm2Proc Natl Acad Sci U S A199895829282979653180
   PubMed Web of Science ®Google Scholar
• PomerantzJSchreiber-AgusNLiegeoisNJThe Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53Cell1998927137239529248
   PubMed Web of Science ®Google Scholar
• MercerWEShieldsMTAminMNegative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53Proc Natl Acad Sci U S A199087616661702143581
   PubMed Web of Science ®Google Scholar
• OhgakiHKleihuesPGenetic Pathways to Primary and Secondary GlioblastomaAm J Pathol20071701445145317456751
   PubMed Web of Science ®Google Scholar
• SherrCJRobertsJMCDK inhibitors: positive and negative regulators of G1-phase progressionGenes Dev1999131501151210385618
   PubMed Web of Science ®Google Scholar
• KerbelRSTumor AngiogenesisN Engl J Med20083582039204918463380
   PubMed Web of Science ®Google Scholar
• ShibuyaMClaesson-WelshLSignal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExp Cell Res200631254956016336962
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF and the quest for tumour angiogenesis factorsNat Rev Cancer2002279580312360282
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol2005231011102715585754
   PubMed Web of Science ®Google Scholar
• BratDJVan MeirEGGlomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis researchAm J Pathol200115878979611238026
   PubMed Web of Science ®Google Scholar
• GerberHPMcMurtreyAKowalskiJVascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activationJ Biol Chem199827330336303439804796
   PubMed Web of Science ®Google Scholar
• YancopoulosGDDavisSGaleNWRudgeJSWiegandSJHolashJVascular-specific growth factors and blood vessel formationNature200040724224811001067
   PubMed Web of Science ®Google Scholar
• JakemanLBWinerJBennettGLAltarCAFerraraNBinding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissuesJ Clin Invest199289244531729274
   PubMed Web of Science ®Google Scholar
• NiederCWiedenmannNAndratschkeNMollsMCurrent status of angiogenesis inhibitors combined with radiation therapyCancer Treat Rev20063234836416713103
   PubMed Web of Science ®Google Scholar
• BelloLLuciniVCarrabbaGSimultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2Cancer Res2001618730873611751392
   PubMed Web of Science ®Google Scholar
• ZagzagDCapoVAngiogenesis in the central nervous system: a role for vascular endothelial growth factor/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic “angiogenic diseases”Histol Histopathol20021730132111813879
   PubMed Web of Science ®Google Scholar
• CarlsonMRPopeWBHorvathSRelationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2Clin Cancer Res2007132592259817473188
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus iri-notecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• JohnsonDHFehrenbacherLNovotnyWFRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or meta-static non-small-cell lung cancerJ Clin Oncol2004222184219115169807
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med20073572666267618160686
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med200334942743412890841
   PubMed Web of Science ®Google Scholar
• WenPYMacdonaldD vdBMReardonDAProposal for updated response criteria in malignant gliomas [abstract]Neurooncology200911622623
   Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol20092774074519114704
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol2009274733474019720927
   PubMed Web of Science ®Google Scholar
• BallmanKVBucknerJCBrownPDThe relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro Oncol20079293817108063
   PubMed Web of Science ®Google Scholar
• WongETHessKRGleasonMJOutcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trialsJ Clin Oncol1999172572257810561324
   PubMed Web of Science ®Google Scholar
• FriedmanHSPetrosWPFriedmanAHIrinotecan therapy in adults with recurrent or progressive malignant gliomaJ Clin Oncol1999171516152510334539
   PubMed Web of Science ®Google Scholar
• PradosMDLambornKYungWKA phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium studyNeuro Oncol2006818919316533878
   PubMed Web of Science ®Google Scholar
• CloughesyTFFilkaEKuhnJTwo studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimenCancer2003972381238612712460
   PubMed Web of Science ®Google Scholar
• RaymondEFabbroMBoigeVMulticentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastomaAnn Oncol20031460361412649109
   PubMed Web of Science ®Google Scholar
• LaiAUpdated results of phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly-diagnosed glioblastomaSociety of Neuro-Onocology Meeting2009 Oct
   Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol19908127712802358840
   PubMed Web of Science ®Google Scholar
• ReesJHSmirniotopoulosJGJonesRVWongKGlioblastoma multiforme: radiologic-pathologic correlationRadiographics19961614131438 quiz 62–638946545
   PubMed Web of Science ®Google Scholar
• PopeWBLaiANghiemphuPMischelPCloughesyTFMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapyNeurology2006661258126016636248
   PubMed Web of Science ®Google Scholar
• AnanthnarayanSBahngJRoringJTime course of imaging changes of GBM during extended bevacizumab treatmentJ Neurooncol20088833934718389177
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res2007131253125917317837
   PubMed Web of Science ®Google Scholar
• JahnkeKMuldoonLLVarallyayCGLewinSJKraemerDFNeuweltEABevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma modelNeuro Oncol20091114215018772353
   PubMed Web of Science ®Google Scholar
• LabidiSIBachelotTRay-CoquardIBevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case seriesClin Breast Cancer2009911812119433393
   PubMed Web of Science ®Google Scholar
• MathewsMSLinskeyMEHassoANFruehaufJPThe effect of bevacizumab (Avastin) on neuroimaging of brain metastasesSurg Neurol20087064965318261776
   PubMedGoogle Scholar
• KarimiSLisEGilaniSD’AmbrosioNHolodnyANonenhancing Brain MetastasesJ Neuroimaging2009
   Web of Science ®Google Scholar
• KunkelPUlbrichtUBohlenPInhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2Cancer Res2001616624662811559524
   PubMed Web of Science ®Google Scholar
• LamszusKBrockmannMAEckerichCInhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherinClin Cancer Res2005114934494016000592
   PubMed Web of Science ®Google Scholar
• TuettenbergJGrobholzRSeizMRecurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapyJ Cancer Res Clin Oncol20091351239124419277712
   PubMed Web of Science ®Google Scholar
• IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology2009731200120619822869
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology20087077978718316689
   PubMed Web of Science ®Google Scholar
• PopeWBDasQHambletonAPatterns of progression in patients with glioblastoma at first or second relapse treated wtih bevacizumab alone or in combination with irinotecan in the BRAIN studyNeuro Oncol200911563699
   Web of Science ®Google Scholar
• HaywardRMPatronasNBakerEHVezinaGAlbertPSWarrenKEInter-observer variability in the measurement of diffuse intrinsic pontine gliomasJ Neurooncol200890576118587536
   PubMed Web of Science ®Google Scholar
• PecaCPacelliRElefanteAEarly clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?Clin Neurol Neurosurg200911133133419117668
   PubMed Web of Science ®Google Scholar
• ChaSKnoppEAJohnsonGWetzelSGLittAWZagzagDIntracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imagingRadiology2002223112911930044
   PubMed Web of Science ®Google Scholar
• HeinPAEskeyCJDunnJFHugEBDiffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injuryAJNR Am J Neuroradiol20042520120914970018
   PubMed Web of Science ®Google Scholar
• SiepmannDBSiegelALewisPJTl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosisClin Nucl Med20053019920015722830
   PubMed Web of Science ®Google Scholar
• PopeWBKimHJHuoJRecurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatmentRadiology200925218218919561256
   PubMed Web of Science ®Google Scholar